Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus bevacizumab vs platinum chemotherapy in first-line ovarian clear cell carcinoma
ChiCTR2600125673Phase 3Recruiting
- Sponsor
- Tongji Hospital
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of QL1706 in clear cell ovarian cancer and epithelial ovarian cancer (EOC) (2 arms), sponsored by Tongji Hospital. Primary endpoint: Progression-Free Survival (PFS). Started May 2026; status: recruiting.
02
Drugs
QL1706
03
Conditions
clear cell ovarian cancerepithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on ChiCTR2600125673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125673.